Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a two-part safety and efficacy study of SKI-606 in subjects who have Philadelphia
chromosome positive leukemias (CML). Part 1 will be a dose-escalation study, in which an
escalating dose of SKI-606 (Bosutinib), up to 600 mg, will be studied in subjects with
imatinib resistant/refractory or imatinib intolerant chronic phase CML. Part 2 will evaluate
the safety and efficacy of the maximum tolerated dose (MTD) of SKI-606 (Bosutinib)identified
in Part 1 of the study.